NewAmsterdam Pharma Co N.V. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NewAmsterdam Pharma Co N.V. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.50M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $45.56M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $14.09M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $102.69M | Feb 26, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($203.82M) | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | ($241.60M) | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | ($176.94M) | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | ($22.63M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($41.79M) | Feb 28, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($225.68M) | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | ($176.29M) | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | ($182.97M) | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | ($3.56M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($34.98M) | Feb 28, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $141.83M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $151.41M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $159.42M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $86.74M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $28.97M | Feb 28, 2024 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $106.35M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $70.45M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $37.63M | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $19.51M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $6.00M | Feb 28, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($147.78M) | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | ($158.56M) | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | ($141.22M) | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | $10.67M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($29.51M) | Feb 28, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $769.28M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $864.62M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $347.10M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $478.50M | Feb 28, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $85.85M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $107.12M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | $58.70M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $48.43M | Feb 28, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $683.43M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $757.50M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $288.39M | Feb 18, 2026 |
| FY2025 | Dec 31, 2022 | $430.07M | Feb 18, 2026 |
| FY2024 | Dec 31, 2021 | ($113.82M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2020 | ($73.04M) | Feb 28, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($762.39M) | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | ($558.57M) | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | ($316.97M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($140.04M) | Feb 28, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $490.00M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | $771.74M | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | $340.45M | Feb 18, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Feb 28, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 18, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Feb 18, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Feb 28, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 114.40M | Feb 18, 2026 |
| FY2025 | Dec 31, 2024 | 108.06M | Feb 18, 2026 |
| FY2024 | Dec 31, 2023 | 82.47M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 81.56M | Feb 28, 2024 |
| FY2025 | Jul 25, 2022 | 36.26M | Feb 18, 2026 |